Oropouche virus
- PMID: 40064505
- PMCID: PMC11908790
- DOI: 10.1503/cmaj.241440
Oropouche virus
Conflict of interest statement
Competing interests:: Jamil Kanji reports payment for advisory board participation for a pharmaceutical agent not approved in Canada. Stephen Vaughan reports honoraria from Pfizer, Ferring, GSK, and Viiv. No other competing interests were declared.
References
-
- Epidemiological update: Oropouche in the Americas region. Washington (DC): Pan American Health Organization, World Health Organization; 2024:1–13. Available: https://www.paho.org/en/documents/epidemiological-update-oropouche-ameri... (accessed 2025 Jan. 13).
-
- Clinical overview of Oropouche virus disease. Atlanta: Centers for Disease Control and Prevention; 2024. Available: https://www.cdc.gov/oropouche/hcp/clinical-overview/index.html (accessed 2024 Sept. 16).
-
- Travel health notices: Oropouche virus disease in the Americas. Ottawa: Public Health Agency of Canada; modified 2024 Nov. 4. Available: https://travel.gc.ca/travelling/health-safety/travel-health-notices/534 (accessed 2024 Sept. 16).
LinkOut - more resources
Full Text Sources